Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Nanox Imaging reports mixed Q3 results amidst growth opportunities

Nanox Imaging reported mixed financial results with revenue of $3.0 million and a gross loss of $2.8 million, while achieving record revenue from USARAD business.
The company showcased strengths in technology deployment, partnerships, and clinical trials, but faces challenges in regulatory clearances and financial performance.
Opportunities exist in market expansion, revenue growth, and operational efficiency improvements to drive future success and profitability.
With a strong focus on innovation, partnerships, and market expansion, Nanox is poised for growth but needs to address regulatory hurdles and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., a leading provider of teleradiology services, has earned The Joint Commission's Gold Seal of Approval® for Ambulatory Health Care Accreditation for the sixth time by demonstrating continuous compliance with its performance standards. The Gold Seal is a symbol of quality that reflects a health care organization's commitment to providing safe and quality patient care.

USARAD, Nanox's Teleradiology Subsidiary, Awarded Accreditation from The Joint Commission

Ironwood Pharma

Cassava Sciences Inc

Investing in the biotech sphere isn't for the faint of heart, and you should steer clear of the biotech stocks to avoid. That's because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals.

Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks

PETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2024. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at https://www.sec.gov/ and on the Company's website at https://www.nanox.vision/ under “Financials” in the Investors section.

Nanox Files 2023 Annual Report on Form 20-F

ASML Hld

Micron Technology

While investors' eyes remain glued on the big names in artificial intelligence, endless other companies are integrating AI technology more quietly. Not every company actively chooses to rebrand as an AI specialist, even while benefiting from its popularity.

Q2 AI Watch: 3 Stocks to Keep Your Eyes On Now

AhealthZ to aid Nanox's pursuit of local authorizations and licenses for Nanox.ARC in South Korea SCL Science to integrate Nanox's artificial intelligence solutions in operations PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ's affiliated company and subsidiary of global healthcare group SCL (Seoul Clinical Laboratories). Under the collaboration, AhealthZ plans to assist Nanox in efforts to secure local authorizations and licenses to enable the importation, marketing and sales of the Nanox.ARC in South Korea.

Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

Nano-X Imaging Ltd. (NNOX) Q4 2023 Earnings Call Transcript

Nanox Launches Nanox.ARC in United States with Installations Across Five States, Marking a Major Advancement in Medical Imaging Management to host conference call and webcast Monday, April 1, 2024 at 8:30 AM ET PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update. Fourth Quarter 2023 Highlights and Recent Developments: Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

The company's low-cost x-ray devices aim to gain traction in overlooked markets. Nano-X typically charges customers for each scan rather than for the hardware itself.

Is Nano-X Imaging Stock a Buy in the New Bull Market?

PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m.

Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024

NVIDIA

SoundHound AI Inc

ARM Holdings PLC

Recursion Pharmaceuticals

Following Nvidia's investment disclosure, SoundHound AI's shares have dramatically increased, tripling in value and boosting its market capitalization to $2.75 billion. The company's success is attributed to its innovative AI voice technology used across various industries, from fast-food to automotive.

Not just Soundhound, these AI stocks are also riding Nvidia wave

– According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming UK National Health Service national average

Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold

In 2021, Nanox acquired a company that was backed by Nvidia. Investors now see that Nvidia owns shares of Nanox but it acquired them indirectly.

Here's Why Nano-X Stock More Than Doubled Last Month

Nvidia disclosed that it owns a small portion of Nano-X Imaging. Nano-X could benefit significantly from teaming up with the chipmaker.

Nano-X Imaging Could Be Teaming Up With Nvidia, and Its Stock Is Flying. Can It Continue?

First patients in clinical study at Beilinson Hospital were scanned with the Nanox.ARC, a stationary X-ray system that produces 3D tomographic images

Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest Diseases

A recent filing unveiled Nvidia's investments in a couple of intriguing healthcare stocks. Nano-X hopes to make medical imaging widely accessible all over the world.

These 2 Healthcare Stocks Are in Nvidia's Portfolio. Should They Be in Yours?

Nvidia (NASDAQ: NVDA ) has been at the center of attention for two years. While the stock had a loyal fanbase before artificial intelligence chips propelled the company past most tech giants, the company's success shined a light on many artificial intelligence (AI) stocks.

Nvidia Is Investing in These 3 Stocks. Should You?

TuSimple Holdings

Nvidia's biggest recent investments were in Arm Holdings and Recursion Pharmaceuticals. The big chipmaker also bought shares of Nano-X Imaging, Soundhound AI, and TuSimple Holdings.

Nvidia Just Invested in These 5 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.

In a surprising turn of events, the stock of Israeli-based medical device company Nano-X Imaging (NASDAQ: NNOX) made a massive rally after technology giant Nvidia (NASDAQ: NVDA) disclosed its positions, and experts see more advances for NNOX stock price in the next 12 months.

Wall Street sets NNOX stock price for the next 12 months

Nvidia is an AI stock that's exciting investors as much as anything else on the market right now. The company recently revealed investments in five AI stocks.

Investors Are Piling Into Nvidia Stock. But Nvidia Is Investing in 5 Other AI Stocks.

Apple

Amazon

Chevron

Elastic N.V

Occidental Petroleum

Tracking 13F filings is crucial for market participants seeking to understand trends, identify potential investment opportunities, and monitor the transactions of Wall Street's most influential investors. Stock Strategist Andrew Rocco breaks down the 3 most important filings this 13F season.

13F Season: 3 Whales to Follow

Shares of smaller artificial intelligence (AI) firms reportedly experienced a rally Thursday (Feb. 15) after Nvidia, the world's leading AI chipmaker, disclosed its stake in them as of Dec. 31. This move by Nvidia offers insights into its growth strategy and highlights its growing influence in the AI world, Reuters reported Thursday.

Shares of Smaller AI Firms Rise After Nvidia Discloses Investments

Through its SEC disclosure, Nvidia provided investors with more evidence of its long-term growth plan.

Small AI Companies Soar After Chip Giant Reveals Stake

Nvidia (NASDAQ: NVDA ) can add boosting a struggling company to its list of recent accomplishments. The Silicon Valley giant recently disclosed investments in several of its tech sector peers, including Nano-X Imaging (NASDAQ: NNOX ).

Nano-X Imaging (NNOX) Stock Soars 50% on Nvidia Investment

As the artificial intelligence (AI) industry continues to evolve, Nvidia (NASDAQ: NVDA) has positioned itself as a key player, recording solid performances and climbing the ranks in terms of company size.

Nano-X Imaging stock jumps on Nvidia's strategic investments

Nvidia disclosed investments in Arm Holdings, SoundHound AI and more in its first-ever 13F SEC filing late Wednesday. ARM rose while SOUN stock soared.

News for Nano-X Imaging Stock (NNOX)